We investigated eribulin as adjuvant therapy after dose-dense doxorubicin and cyclophosphamide for patients with human epidermal growth factor receptor 2enegative early-stage breast cancer. The primary end point of feasibility of this regimen was not met, even with mandatory prophylactic growth factor support with eribulin treatment. Unexpected adverse events were not observed with this regimen, and most patients were able to receive full doses without dose delay or reduction. Background: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ! 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. Patients and Methods: Patients with human epidermal growth factor receptor 2enegative, stage I to III breast cancer received doxorubicin 60 mg/m 2 and cyclophosphamide 600 mg/m 2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1.4 mg/m 2 provided intravenously on days 1 and 8 every 21 days. There were 2 cohorts, as follows:
Introduction
Breast cancer is the most frequently diagnosed cancer among women. 1 An estimated 266,120 new cases of breast cancer will be diagnosed in 2018 in the United States, accounting for 15% of total cancer cases. 2 Anthracycline-and taxane-containing adjuvant regimens are a standard of care for the treatment of early-stage breast cancer in women who are at high risk for recurrence, with dose-dense therapy demonstrating improved overall survival (OS) over conventional scheduling. 3, 4 Although there has been progress in the development of adjuvant systemic therapy for breast cancer, there is still a significant unmet medical need for patients with high-risk or poor-prognosis early-stage breast cancer. 5 Eribulin is a microtubule inhibitor that belongs to the halichondrin class of antineoplastic drugs. 6 It is a pharmaceutically optimized, fully synthetic analog of halichondrin B, a naturally occurring macrolide isolated from the marine sponge Halichondria okadai. 7 Eribulin has a novel mode of action that is distinct from that of other tubulintargeting drugs including both taxanes and vinca alkaloids: it induces irreversible mitotic blockade by binding to a small number of high-affinity sites on the growing (plus) ends of microtubules to inhibit their growth, but has no measurable effect on microtubule shortening. 8, 9 Eribulin also exhibits a range of additional, nonmitotic, complex effects on tumor biology, including induction of vascular remodeling, suppression of cancer-cell migration and invasion, and reversal of the epithelial-to-mesenchymal transition. [10] [11] [12] Eribulin is approved for the treatment of patients with metastatic breast cancer who have previously received at least 2 (in the United States) or at least 1 (in the European Union) chemotherapeutic regimens in the metastatic setting, including an anthracycline and a taxane in any setting. [13] [14] [15] The efficacy and safety of eribulin have been demonstrated in a number of trials in patients with anthracycline-and taxane-pretreated metastatic breast cancer 15 and in patients in an earlier-line chemotherapeutic setting. 16, 17 The survival benefit of eribulin in patients with advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative disease provides a rationale for assessing the efficacy of eribulin in the adjuvant setting. This phase 2, single-arm, open-label study assessed the feasibility of administering eribulin as adjuvant therapy after dose-dense doxorubicin and cyclophosphamide (AC) in patients with early-stage (I to III) HER2-negative breast cancer.
Patients and Methods

Patients
Eligible patients were ! 18 years old with histologically confirmed diagnosis of stage I to III invasive breast cancer that was HER2-negative. HER2-negative status was defined as an immunohistochemistry score of 0/1þ or an absence of HER2 amplification as determined by fluorescence in-situ hybridization. Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and had adequate cardiac, renal, bone marrow, and liver function. Key exclusion criteria included prior chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer, nonmalignant systemic disease that would preclude any of the study drugs, and patients with a concurrently active second malignancy other than adequately treated nonmelanoma skin cancers or in situ cervical cancer. In the original study design (cohort 1), after entry to the eribulin treatment phase, growth factor (pegfilgrastim or filgrastim) was administered only at the treating physician's discretion after a neutropenic event. However, because of the number of neutropenic events during the eribulin portion of this regimen, the study design was amended to include a second cohort (cohort 2) in which administration of prophylactic growth factor with eribulin therapy was required. Cohort 2 received an empirically designed short course of prophylactic filgrastim at a dose of 300 mg for patients 60 kg or 480 mg for patients > 60 kg that was self-administered subcutaneously on days 3, 4, 10, and 11 of each eribulin 21-day cycle.
Study Design and Treatment
This study was conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki, and the protocol was approved by an Institutional Review Board. All patients provided informed consent prior to any study-specific procedures being performed.
End Points and Assessments
The primary end point was feasibility of dose-dense AC for 4 cycles followed by eribulin for 4 cycles in the adjuvant setting. Feasibility was defined as the percentage of patients who completed the eribulin portion of the regimen without a dose omission, delay, or reduction due to an eribulin-related AE. A dose delay was defined as a delay due to an eribulin-related AE of > 2 days for subsequent doses or cycles after the full dose of eribulin was administered. A feasibility rate of 80% was set as the threshold, based on historical data from adjuvant trials in which > 80% of patients completed the intended treatment regimen without dose delay or reduction. [18] [19] [20] [21] Patients were considered not evaluable if there was an event of study drug dose omission, delay, reduction, or withdrawal for which eribulin could be excluded as the attribution agent. Relative dose intensity (RDI) of eribulin treatment was defined as the total actual dose of eribulin divided by the total planned dose of eribulin.
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The secondary end point was to evaluate the toxicities associated with 4 cycles of AC followed by 4 cycles of eribulin. Safety assessments included monitoring and recording of all AEs and serious AEs (SAEs) based on the National Cancer Institute's Common Terminology Criteria for Adverse Events v4.0. Exploratory end points included 3-year disease-free survival (DFS) and 3-year OS.
Statistical Analysis
The full analysis set comprised all patients who received at least 1 dose of AC, and the eribulin-treated analysis set comprised all patients who received at least 1 dose of eribulin. The safety analysis set comprised all patients who were enrolled, received at least 1 dose of study treatment, and had at least 1 posttreatment safety assessment. The eribulin-treated safety analysis set comprised all patients who were enrolled, received at least 1 dose of eribulin treatment, and had at least 1 safety assessment after eribulin treatment.
Feasibility rates were calculated separately for each of the 2 cohorts. The proportion of patients who completed the eribulin portion of the regimen without a dose omission, delay, or reduction due to an eribulin-related AE were estimated via the observed completion rate, and an exact 90% confidence interval (CI) was constructed. Three-year DFS and 3-year OS were analyzed by the Kaplan-Meier method and were summarized for the overall study population and the 2 individual cohorts.
Results
Patients
In this phase 2 study, 84 patients were enrolled, 3 of whom were screen failures, resulting in 81 patients entering the study-treatment phase (n ¼ 55 patients in cohort 1; n ¼ 26 patients in cohort 2) (Figure 2) . While all 81 patients received AC treatment, 2 patients (1 in each cohort) did not receive eribulin after AC treatment (patient choice, n ¼ 1; per protocol due to > 2 weeks of treatment delays, n ¼ 1). The Eribulin Treatment in Early-Stage Breast Cancer remaining 79 patients received eribulin after AC treatment (n ¼ 54 in cohort 1; n ¼ 25 in cohort 2) (Figure 2 ). Demographic and baseline characteristics were generally similar between cohorts (Table 2 ).
Patients had a median age of 49 years (range, 26-69 years). The majority of the patients were white (67.9%). Demographic and baseline characteristics were generally similar between cohorts, however there were more African American patients in cohort 2. African Americans comprised 18.5% of the total patient population and 30.8% of the patients in cohort 2. The majority of patients (85.2%) had an ECOG performance status of 0.
Feasibility
Of the 81 patients who received study treatment, 73 (90%) were considered evaluable for feasibility. Of the 8 nonevaluable patients, 2 patients did not receive eribulin treatment, 2 discontinued treatment (patient choice, progressive disease) and the remaining 4 patients had 5 AEs (hypertension, paronychia, pyrexia, upper respiratory infection, tooth abscess) leading to study drug dose omissions, delays, reductions, or withdrawals that were not attributable to eribulin. The feasibility threshold of 80% was not reached in either cohort 1 or cohort 2 (Table 3) , with a feasibility rate of 72.9% (90% CI, 60.4, 83.2) in cohort 1 and 60.0% (90% CI, 41.7, 76.4) in cohort 2. There was no difference in the feasibility rate between cohorts (P ¼ .2958).
Exposure and Safety
The extent of exposure to eribulin in the eribulin-treated analysis set is summarized in Table 4 . Of the 79 patients who received eribulin after dose-dense AC, 71 (89.9%) completed study treatment. The mean RDI per patient was 92.0% in cohort 1 and 90.9% in cohort 2 ( Table 4) .
The most frequent (!30%, any grade) eribulin-related treatmentemergent AEs (TEAEs) were fatigue (n ¼ 60, 75.9%), peripheral neuropathy (n ¼ 43, 54.4%), nausea (n ¼ 31, 39.2%), and neutropenia (n ¼ 28, 35.4%). Eribulin-related TEAEs of all grades that occurred in at least 10% of patients in either cohort, and TEAEs that occurred at grades 3 or 4 are summarized in Table 5 . The most common hematologic TEAE was neutropenia, with an overall incidence of 35.4% (n ¼ 28; grade 3/4: 27.8%, n ¼ 22). Neutropenic events (any grade) were reported in 31.5% (n ¼ 17) of patients in cohort 1 and 44.0% (n ¼ 11) of patients in cohort 2. Eribulin-related febrile neutropenia occurred in 2 patients (both grade 3), 1 in each cohort. The timing of dose delays due to neutropenia was variable across both cohorts and occurred on both cycle day 1 and day 8 (Supplemental Table 1 in the online version).
In the eribulin-treated safety analysis set (n ¼ 79), 3 patients in cohort 1 (5.6%) and 0 patients in cohort 2 discontinued study 
Survival
As of data cutoff (28 Apr 2015), the 3-year DFS rate for patients in the eribulin-treated analysis set was 89.5%. Three patients developed metastatic breast cancer and 2 patients had ipsilateral locoregional recurrence. The median follow-up times for DFS were 32.2 months (range, 2.6-44.8 months) for cohort 1 and 12.9 months (range, 3.8-20.4 months) for cohort 2. Median DFS was not evaluable at the time of analysis.
The 3-year OS rate for patients in the eribulin-treated analysis set was 97.1%. 3 Patients (3.8%) died of progressive disease. The median follow-up times for OS were 33.9 months (range, 4.2-44.8 months) for cohort 1 and 12.9 months (range, 4.8-20.4 months) for cohort 2. Median OS was not evaluable at the time of analysis.
Discussion
The aim of this phase 2 study was to evaluate the feasibility of administering eribulin as an adjuvant therapy after dose-dense AC in patients with early-stage HER2-negative breast cancer. In the pivotal EMBRACE (eribulin monotherapy vs. treatment of physician's choice [TPC] in patients with metastatic breast cancer) phase 3 study, eribulin demonstrated a statistically significant OS advantage in patients with heavily pretreated metastatic breast cancer compared with TPC (13.1 months vs. 10.6 months for eribulin and TPC, respectively; hazard ratio [HR] 0.81, 95% CI, 0.66-0.99; P ¼ .041) with a manageable safety profile. 15 A subgroup analysis from a subsequent phase 3 study (Study 301) that evaluated eribulin versus capecitabine in the first-, second-, or third-line setting for advanced/metastatic disease found that HER2-negative patients treated with eribulin demonstrated an OS benefit of 2.4 months (15.9 vs. 13.5 months for eribulin and capecitabine, respectively; HR 0.84; P ¼ .03). 22 Further, in a pooled analysis of the EMBRACE and 301 studies, eribulin treatment significantly prolonged OS compared with control treatment in subgroups of patients with HER2-negative disease (15.2 vs. 13.3 months; HR 0.82; P ¼ .002) and with triple-negative disease (12.9 vs. 8.2 months; HR 0.74; P ¼ .006). 23 Additionally, evidence from phase 2 trials demonstrated the clinical activity of eribulin in the first-line setting in locally recurrent or metastatic HER2-negative breast cancer. 16, 24 These compelling data in support of the clinical activity of eribulin for metastatic breast cancer led to interest in incorporating eribulin into an anthracycline-based adjuvant regimen. Dose-dense chemotherapy with anthracycline and paclitaxel is a preferred regimen for HER2-negative breast cancer in the adjuvant/ neoadjuvant setting. 3 However, common adverse events observed with taxanes include neuropathy, myalgia, and arthralgia. 25 The most frequent (!30%, any grade) eribulin-related TEAEs were fatigue, peripheral neuropathy, nausea, and neutropenia. All of these TEAEs are consistent with the known safety profile of eribulin in breast cancer. Neutropenia was the most common hematologic TEAE, occurring in 35.4% of patients (at any grade) and 27.8% of patients (at grade 3/4). Phase 2 clinical trial data suggest that eribulin may exhibit less neurotoxicity and myalgia/arthralgia compared to ixabepilone. 26 Although the patient numbers in this study are small, grade 3/4 peripheral neuropathy occurred in 1% of total patients, which is thought-provoking in the setting of adjuvant breast cancer therapy where neuropathy may have long-term impact on quality of life. 27 Previous data have suggested that taxane therapy in the adjuvant treatment of breast cancer, is associated with grade 3/4 peripheral neuropathy rates of 6% to 10%. 28, 29 As of data cutoff (28 Apr 2015) , the 3-year DFS and the 3-year OS rates for all patients were 89.5% and 97.1%, respectively. At the time of analysis, median DFS and median OS were nonevaluable. The median follow-up times for DFS were 32.2 months (range, 2.6-44.8 months) for cohort 1 and 12.9 months (range, 3.8-20.4 months) for cohort 2. Median follow-up times for OS were 33.9 months (range, 4.2-44.8 months) for cohort 1 and 12.9 months (range, 4.8-20.4 months) for cohort 2. Feasibility was the primary end point of this study. Data from previous studies indicate that more than 80% of the patients in standard adjuvant trials completed the planned therapeutic regimen without a dose delay or reduction. 18, 19, 21 Therefore, the target for feasibility for this phase 2 study was set at 80%. However, this target was not met for either cohort, primarily driven by the incidence of neutropenia-the most common treatment-related TEAE leading to eribulin dose reduction or interruption. 2 ). In addition, the average relative dose intensities for eribulin in eribulin-treated patients were greater than 90% in both cohorts. The administration of eribulin after dosedense AC in patients was well-tolerated, with very few patients (4%) discontinuing eribulin because of TEAEs. An alternative dosing schedule for administering growth factor may contribute to a more favorable tolerability profile for AC followed by eribulin treatment. It is noteworthy that growth factor in this study was administered as a short course on days 3, 4, 10, and 11 of eribulin cycles. Changes in the quantity and/or frequency of growth factor support after eribulin treatment may have an impact on observed neutropenia rates and warrants consideration of further investigation in this setting. However, the design and selection of an appropriate granulocyte colony-stimulating factor (G-CSF) regimen requires a balance between functional adequacy (ie, controlling neutropenia), patient and physician practicality, and economic feasibility. These factors contributed to the empirical design of the G-CSF schedule in this study, with the goal of safely managing neutropenia while minimizing impact to patients.
The treatment sequence of an anthracycline-based regimen followed by a taxane is traditional of adjuvant trials of taxanes in early breast cancer; this is primarily due to the introduction of anthracyclines into clinical practice prior to taxanes. Several studies evaluating the role of different anthracycline and taxane sequences in the adjuvant setting have demonstrated that the reverse sequence is acceptable. 30 For example, in a randomized phase 2 study of patients with node-positive breast cancer, dose-dense docetaxel followed by doxorubicin and cyclophosphamide resulted in fewer dose reductions (46% vs. 18%) than the reverse sequence. 31 The administration of eribulin prior to dose-dense AC may improve the feasibility of this regimen, but requires formal investigation in this setting.
Conclusion
The primary end point of feasibility for eribulin after dose-dense AC was not met. Further, amendment of the protocol to include the administration of an empirically designed brief (2-day) duration of growth factor after eribulin treatment did not improve feasibility. Nevertheless, eribulin treatment as an adjuvant therapy after dose-dense AC in patients with early-stage HER2-negative breast cancer was tolerable and the majority of patients completed the planned treatment with no dose delay or reduction. Further investigation into alternative dosing schedules or use of growth-factors is recommended.
Clinical Practice Points
Dose-dense chemotherapy with sequential paclitaxel is a preferred regimen for HER2-negative breast cancer in the adjuvant/neoadjuvant setting. However, common adverse events observed with taxanes include neuropathy, myalgia, and arthralgia. The efficacy and safety of eribulin have been demonstrated in a number of randomized phase 3 trials in patients with anthracycline-and taxane-pretreated metastatic breast cancer and in patients in an earlier-line chemotherapeutic setting. Eribulin is a microtubule inhibitor that has a novel mode of action that is distinct from that of other tubulin-targeting drugs, including both taxanes and vinca alkaloids. Eribulin exhibits a range of additional, nonmitotic, complex effects on tumor biology, including induction of vascular remodeling, suppression of cancer cell migration and invasion, and reversal of the epithelial-to-mesenchymal transition. Given its clinical activity in improving OS in patients with locally recurrent or metastatic breast cancer, we aimed to investigate eribulin in the adjuvant setting after dose-dense AC. In this study, the primary end point of feasibility for the regimen was not met. Further, amendment of the protocol to include the administration of an empirically designed brief duration of growth factor after eribulin treatment did not improve feasibility. Nevertheless, eribulin treatment as an adjuvant therapy after dose-dense AC in patients with early-stage HER2-negative breast cancer was tolerable because the majority of patients completed the planned treatment with no dose delay or reduction. Further investigation of this regimen with alternative dosing schedules or use of growth factors is recommended.
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